Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.

Cancer research - 1 Feb 2024

Heo Jinho, Kim Yoo-Na, Shin Saeam, Lee Kyunglim, Lee Ji-Hyun, Lee Yong Jae, Choi Zisun, Park Jihyang, Min Seungki, Kim Sang Wun, Choi Jong Rak, Kim Sunghoon, Lee Seung-Tae, Lee Jung-Yun

Abstract excerpt

Circulating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. Here, we aimed to assess the clinical utility of serial ctDNA testing using tumor-naïve, small-sized next-generation sequencing (NGS) panels. A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 38038965
DOI: 10.1158/0008-5472.CAN-23-1429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.PMID 38038965Read ↗

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian CancerSemantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.Semantic proximity Read ↗

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.Semantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Advances in application of circulating tumor DNA in ovarian cancer.Semantic proximity Read ↗

Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted TherapySemantic proximity Read ↗

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted TherapeuticsSemantic proximity Read ↗

Next‐generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug‐resistant recurrent ovarian cancerSemantic proximity Read ↗

Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.